An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth

Title:An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth

Volume: 11 Issue: 3

Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer

Affiliation:

• European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe,Germany

Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.

Abstract: Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.

Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

Cite this article as:

Morgenstern Alfred*, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek and Bruchertseifer Frank, An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth, Current Radiopharmaceuticals 2018; 11 (3) . https://dx.doi.org/10.2174/1874471011666180502104524